- Home
- BRT vs ENGN Comparison
BRT vs ENGN Comparison
Compare BRT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- ENGN
- Stock Information
- Founded
- BRT 1972
- ENGN 1999
- Country
- BRT United States
- ENGN Canada
- Employees
- BRT N/A
- ENGN N/A
- Industry
- BRT Real Estate Investment Trusts
- ENGN
- Sector
- BRT Real Estate
- ENGN
- Exchange
- BRT Nasdaq
- ENGN Nasdaq
- Market Cap
- BRT 331.7M
- ENGN 297.7M
- IPO Year
- BRT N/A
- ENGN N/A
- Fundamental
- Price
- BRT $18.21
- ENGN $5.15
- Analyst Decision
- BRT Strong Buy
- ENGN Buy
- Analyst Count
- BRT 3
- ENGN 9
- Target Price
- BRT $22.17
- ENGN $25.22
- AVG Volume (30 Days)
- BRT 22.2K
- ENGN 44.3K
- Earning Date
- BRT 05-07-2025
- ENGN 03-10-2025
- Dividend Yield
- BRT 5.56%
- ENGN N/A
- EPS Growth
- BRT N/A
- ENGN N/A
- EPS
- BRT N/A
- ENGN N/A
- Revenue
- BRT $97,274,000.00
- ENGN N/A
- Revenue This Year
- BRT N/A
- ENGN N/A
- Revenue Next Year
- BRT $5.39
- ENGN N/A
- P/E Ratio
- BRT N/A
- ENGN N/A
- Revenue Growth
- BRT 1.65
- ENGN N/A
- 52 Week Low
- BRT $15.81
- ENGN $4.42
- 52 Week High
- BRT $20.22
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- BRT 54.89
- ENGN 35.95
- Support Level
- BRT $17.30
- ENGN $4.85
- Resistance Level
- BRT $18.50
- ENGN $5.60
- Average True Range (ATR)
- BRT 0.65
- ENGN 0.53
- MACD
- BRT 0.01
- ENGN -0.00
- Stochastic Oscillator
- BRT 53.22
- ENGN 25.69
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.